Efficacy of splenectomy for hypersplenic patients with advanced hepatocellular carcinoma

被引:22
作者
Hirooka, Masashi [1 ]
Ishida, Kiyotaka [1 ]
Kisaka, Yoshiyasu [1 ]
Uehara, Takahide [1 ]
Watanabe, Yuji [2 ]
Hiasa, Yoichi [1 ]
Michitaka, Kojiro [1 ]
Onji, Morikazu [1 ]
机构
[1] Ehime Univ, Grad Sch Med, Dept Gastroenterol & Metabol, Onsen, Japan
[2] Ehime Univ, Grad Sch Med, Dept Organ Regenerat Surg, Onsen, Japan
关键词
Hepatocellular carcinoma; chemotherapy; splenectomy;
D O I
10.1111/j.1872-034X.2008.00389.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim: Chemotherapy for advanced hepatocellular carcinoma (HCC) patients with hypersplenism is generally unsatisfactory, as a lower-dose therapy is usually administered. Splenectomy may represent a better approach to overcoming the complication due to hypersplenism in patients with advanced HCC. This retrospective study was conducted to evaluate whether HCC patients who undergo splenectomy show improved prognosis. Methods: We examined 34 HCC patients. Twenty-two had thrombocytopenia and/or leucopenia and underwent laparoscopic splenectomy. The completion rate of full-dose drug regimens, the response rate, the toxicity of chemotherapy and the cumulative survival rate were compared between the splenectomy and non-splenectomy groups. Results: The response rate and the cumulative survival rate in the splenectomy group were significantly better than that in the non-splenectomy group. Conclusions: Splenectomy is an efficient method for advanced HCC patients with hypersplenism treated by chemotherapy.
引用
收藏
页码:1172 / 1177
页数:6
相关论文
共 21 条
  • [1] Ando E, 1997, CANCER-AM CANCER SOC, V79, P1890, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1890::AID-CNCR8>3.0.CO
  • [2] 2-K
  • [3] Role of spleen enlargement in cirrhosis with portal hypertension
    Bolognesi, M
    Merkel, C
    Sacerdoti, D
    Nava, V
    Gatta, A
    [J]. DIGESTIVE AND LIVER DISEASE, 2002, 34 (02) : 144 - 150
  • [4] Cao ZX, 2003, WORLD J GASTROENTERO, V9, P2460
  • [5] Use of hepatectomy and splenectomy to treat hepatocellular carcinoma with cirrhotic hypersplenism
    Chen, XP
    Wu, ZD
    Huang, ZY
    Qiu, FZ
    [J]. BRITISH JOURNAL OF SURGERY, 2005, 92 (03) : 334 - 339
  • [6] HIRAI K, 1986, HEPATO-GASTROENTEROL, V33, P105
  • [7] A MULTIVARIATE-ANALYSIS OF RISK-FACTORS FOR HEPATOCELLULAR CARCINOGENESIS - A PROSPECTIVE OBSERVATION OF 795 PATIENTS WITH VIRAL AND ALCOHOLIC CIRRHOSIS
    IKEDA, K
    SAITOH, S
    KOIDA, I
    ARASE, Y
    TSUBOTA, A
    CHAYAMA, K
    KUMADA, H
    KAWANISHI, M
    [J]. HEPATOLOGY, 1993, 18 (01) : 47 - 53
  • [8] *LIV CANC STUD GRO, 1997, CLASS PRIM LIV CANC
  • [9] A statistical simulation study finds discordance between WHO criteria and RECIST guideline
    Mazumdar, M
    Smith, A
    Schwartz, LH
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2004, 57 (04) : 358 - 365
  • [10] RANDOMIZED TRIAL OF EFFECTS OF INTERFERON-ALPHA ON INCIDENCE OF HEPATOCELLULAR-CARCINOMA IN CHRONIC ACTIVE HEPATITIS-C WITH CIRRHOSIS
    NISHIGUCHI, S
    KUROKI, T
    NAKATANI, S
    MORIMOTO, H
    TAKEDA, T
    NAKAJIMA, S
    SHIOMI, S
    SEKI, S
    KOBAYASHI, K
    OTANI, S
    [J]. LANCET, 1995, 346 (8982) : 1051 - 1055